Akesis Names John L. Capicchioni as New President
Published: May 30, 2012
CHARLOTTE, N.C., May 30, 2012 /PRNewswire/ -- Akesis LLC, a leading contract research firm specializing in phase II-IV clinical dermatology services and regulatory affairs consulting, today announced that it has named John L. Capicchioni as its new President. Mr. Capicchioni will be responsible for providing strategic leadership and managerial oversight of the company while driving growth and assuring quality, cost optimization, and best business practices to pharmaceutical, device, generic, formulation development and biotechnology companies.
"I am excited to be joining Akesis as President at this critical time," Mr. Capicchioni said. "With nearly 60 dermatology development programs to its credit, Akesis has a solid record of success in the CRO marketplace and is positioned to be a leader and innovator in clinical research efforts globally. I look forward to identifying new growth opportunities and to shepherding the firm to the next level of knowledge leadership, customer advocacy, performance and professionalism."
Mr. Capicchioni brings 22 years of global CRO experience to Akesis. He has held a broad range of executive leadership positions, overseeing global sales, project management, marketing, and client services. Mr. Capicchioni was Senior Vice President of Business Development for Global Early Clinical and Bioanalytical Research at MDS Pharma Services (now Celerion), where he directed the pharmaceutical and generic segments, and previously held senior posts at Phoenix International Life Sciences. He has served on the board of directors of the Generic Pharmaceutical Association as the elected member for Contract Research Organizations. Mr. Capicchioni holds a Chemistry degree from Rutgers University.
"John is well-known in the industry for his leadership, integrity, energy and passion," said Dr. Murray P. Ducharme, President and CEO of Learn and Confirm Inc. "With his strong strategic focus, understanding of the marketplace and commitment to all stakeholders, he will lead the company in delivering services that ensure patient safety coupled with cost and scheduling efficiencies for sponsors, ultimately helping his clients' businesses grow."
"Our clients demand expertise that guides product safely to market," said Mr. Capicchioni, "and that brings the most cost-effective and clinically rigorous solutions to bear. As President, I will lead the Akesis team in providing a unique form of customer advocacy, emphasizing quality, accountability, timeliness and budget management in all aspects of our customer-focused clinical research initiatives and regulatory practice."
Akesis is a quality-driven global contract research organization whose focus is purely dermatology clinical research services and regulatory affairs consulting, serving pharmaceutical, device, generic, formulation development and biotechnology companies. Akesis provides pharmaceutical development services, including program development and management, oversight of Phase I trials, conduct of Phase II-IV trials, 510(k) planning and application preparation, GLP/GCP/GMP auditing, and ANDA and 505(b)(2) NDA submission preparation, that help clients meet regulatory standards, maintain compliance, and assure quality.
Zaidoon A. Al-Zubaidy
SOURCE Akesis LLC